GE HealthCare Technologies (GEHC) Stock Forecast & Price Target

GE HealthCare Technologies
Bull Case

Here are some ways that investors could benefit from investing in GE HealthCare Technologies Inc.:

• GE HealthCare Technologies Inc. recently reported third-quarter earnings that exceeded analyst expectations, with earnings per share of $1.34 compared to a consensus estimate of $1.20, and revenue of $5.51 billion which surpassed the projected $5.35 billion, demonstrating strong operational performance and top-line growth of 7.2% year-over-year.
• The company has raised its full-year 2026 earnings outlook following strong third-quarter results, signaling management confidence in continued momentum, while the stock currently trades at $85.81, reflecting a positive market reaction to these improved financial projections.
• Wall Street sentiment has shifted positively, with Barclays raising its price target to $95.00 and issuing an overweight rating, while BTIG Research increased its target to $83.00 with a buy rating, indicating that major institutional investors see significant upside potential in the stock.
• Insider confidence is high, as CEO Peter J. Arduini and CFO James Saccaro both made significant purchases of company stock in late April and early May 2026, suggesting that key executives believe the shares are undervalued relative to their long-term potential.
• GE HealthCare Technologies Inc. is expanding its technological leadership by launching new AI-enabled products, such as the Allia Celeo ceiling-mounted interventional system introduced at the TCT 2026 conference, which integrates AI-powered precision imaging to enhance procedural flow and patient throughput in clinical settings.